Lung cancer is one of the most common cancers and has became a predominant cause of cancer-related death throughout the world. The k-ras codon 12 mutation, which is the most common lung cancer mutation, is found in 15 to 30% of all lung cancers. Furthermore, the p53 gene has a very important role in the biological properties of tumor cells, and it is mutated in about 50% of non-small cell lung cancers. Residual tumor cells remain in surgical margins diagnosed as tumor free by histopathological techniques, and they can play a role in forming any local recurrence. Molecular methods may be exploited that are sensitive enough to detect small numbers of tumor cells.
Methods
In the present study, we examined p53 gene mutations and k-ras codon 12 mutations from the tumor samples and surgical margins of 34 non-small-cell lung cancer patients. P53 gene mutations were analyzed by single strand conformational polymorphism analysis, heterodublex analysis and DNA sequencing. K-ras codon 12 mutations were analyzed by the mutagenic PCR-restricted fragment length polymorphism method.
Results
A p53 mutation was detected only in primary tumors of 3 out of 34 patients (8.82%). These mutations were clustered in exon 5. Moreover, a k-ras codon 12 mutation was detected in both the primary tumor and the surgical margin tissues of 2 out of 34 patients (5.88%).
Conclusions
The detected mutation rate was low, in the range given in the literature. We think that different mechanisms related to other genes and individual genetic differences might play a role in cancer formation in our study group. We believe that molecular studies are necessary to identify biomarkers and to determine genetic alterations in histopathologically normal surgical margins.
MasasyesvaB.G., TongB.C., BrockM.V., PilkingtonT., GoldenbergD., SidranskyD., HardenS., WestraW.H., CalifanoJ.: Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer.Int J Cancer,113(6): 1022–1025, 2005.
9.
LevineA.J.: P53, the cellular gatekeeper for growth and division.Cell, 88: 323–331, 1997.
10.
MaoL.: Molecular abnormalities in lung carcinogenesis and their potential clinical implications.Lung Cancer,34(Suppl 2): 27–34, 2001.
11.
KishimotoY., MurakamiY., ShirashiM., HayashiK., SekiyaT.: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.Cancer Res, 52: 4799–4804, 1992.
HuncharekM., MuscatJ., GeschwindJ.F.: K-ras oncogene mutation as a prognostic marker in NSCLC: a combined analysis 881 cases.Carcinogenesis, 20: 1507–1510, 1999.
14.
MinamotoT., MasayoshiM., Ze'evR.: K-ras mutation: Early detection in molecular diagnosis and risk assessment of colorectal, pancreas and lung cancers - a review.Cancer Detect Prev, 241: 1–12, 2000.
15.
GealyR., ZhangL., SiegfriedJ.M., LuketichJ.D., KeohavongP.: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.Cancer Epidemiol Biomarkers Prev, 8: 297–302, 1999.
16.
KeohavaongP., LanQ., GaoW.M., DeMariniD.M., MassM.J., LiX.M., RoopB.C., WeissfeldJ., TianD., JudyL.M.: K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China.Lung Cancer, 41: 21–27, 2003.
17.
RodenhuisS., SlebosR.J.: Clinical significance of ras oncogene activation in human lung cancer.Cancer Res, 52: 2665–2669, 1992.
18.
GrazianoS.L., GambleG.P., NewmanN.B., AbbottL.Z., RooneyM., MookherjeeS.: Prognostic significance of k-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.J Clin Oncol, 17: 668–675, 1999.
19.
ImmermannS.C., VanecoR.M., FryW., HeadL.R., ShieldsT.W.: Site of recurrence of patients with stages I and II carcinoma of the lung resected for cure.Ann Thorac Surg, 32: 23–27, 1981.
20.
FeldR., RubensteinL., WeisenburgerT.: Site of recurrence in resected Stage I non-small-cell lung cancer: a guide for future studies.J Clin Oncol, 2: 1352–1358, 1984.
21.
ZienolddinyS., RybergD., ArabMo, SkaugV., HagenA.: Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.Br J Cancer, 84: 226–231, 2001.
22.
HongyoT., BuzardG.S., PalliD., WeghorstC.M., AmorosiA., GalliM., CaporasoN.E., FraumeniJ.F., RiceJ.M.: Mutations of the k-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy.Cancer Res, 55, 2665–2672, 1995.
23.
SangerF., NicklenS., CaulsonA.R.: DNA sequencing with chain terminating inhibitors.Proc Natl Acad Sci USA, 74, 463–467, 1977.
D'amicoT.A., AloiaT.A., MooreM.B.H., HerndonJ.E., BrooksK.R., LauC.L., HarpoleD.H.: Molecular biologic substaging of stage I lung cancer according to gender and histology.Ann Thorac Surg, 69: 882–886, 2000.
27.
BodnerS.M., MinnaJ.D., D'AmicoD., CarboneD., MitsudomT., FedercoJ., BuchhagenD.L., NauM.M., GazdarA.F., LinnoilaR.I.: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.Oncogene, 7: 743–749, 1992.
28.
RainovN.G., DobbersteinK.U., FittkauM., BahnH., HolzausenH.J., GantchevL., and BurkertW.: Absence of p53 antibodies in sera from glioma patients. Clin.Cancer Res, 1: 775–781, 1995.
29.
HarafD.J., NodzenskiE., BrachmanD., MickR., MontagA., GravesD., VokesE.E., WeichselbaumR.R.: Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival.Clin Cancer Res, 2: 755–762, 1996.
30.
TriversG.E., De BenedettiV.M.G., CawleyH.L., CaronG., HarringtonA.M., BennettW.P., JettJ.R., ColbyT.V., TazelaarH., PairoleroP., MillerR.D., HarrisC.C.: Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.Clin Cancer Res, 2: 1767–1775, 1996.
31.
KiharaC., SekiT., FurukawaY., YamanaH., KimuraY., Van SchaardenburghP., HirataK., NakamuraY.: Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal cancer patients.Jpn J Cancer Res, 91: 190–198, 2000.
32.
OzcelikH., MoussesS, AndrulisI.L.: Low levels of expression of an inhibitor of cyclin dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations.Clin Cancer Res, 1: 907–912, 1995.
33.
SuzukiY., OritaM., ShiraishiM., HayashiK., SekiyaT.: Detection of ras gene mutations in human lung cancers by SSCP Analysis of PCR Products.Oncogene, 5: 1037–1043, 1990.
34.
MitsudomiT., VialletJ., MulshineJ.L., LinnoilaR.I., MinnaJ.D., GazdarA.F.: Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines.Oncogene, 6: 1353–1362, 1991.
35.
CampsC., SireraR., BremnesR., BlascoA., SanchoE., BayoP., SafontM.J., S'anchezJ.J., Tar'onM., RosellR.: Is there a prognostic role of k-ras point mutations in the serum of patients with advanced non-small cell lung cancer?Lung Cancer,50: 339–346, 2005.
36.
HoutenV.M.M., TaborM.P., BrekelM.W.M., KummerA., DenkersF., DijikstraJ., LeemansR., WallI., SnowG.B., BrakenhoffR.H.: Mutated p53 as a molecular marker for the diagnosis of the head and neck cancer.Pathology, 198: 476–486, 2002.
37.
MaoL., LeeJ.S., FanY.H., RoJ.Y., BatsakisJ.G., LippmanS., HittelmanW., HongW.K.: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their valur in cancer risk assessment.Nature Med, 2: 682–685, 1996.
38.
RosinM.P., ChengX., PohC., LamW.L., HuangY., LovasJ., BreanK., EpsteinJ.B., PriddyR., LeeN.D., ZhangL.: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.Clin Cancer Res, 6: 357–362, 2000.
39.
PatridgeM., PateromichelakisS., PhilipsE., EmilionG.G., A'HernR.P., LangdonJ.D.: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma with in a field of cancerization.Cancer Res, 60: 3893–3898, 2000.
40.
YakutT., EgeliU., GebitekinC.: Investigation of c-myc and p53 gene alterations in the tumor and surgical border tissues of NSCLC and effects on clinicopathologic behavior: By the FISH Technique.Lung, 181: 245–258, 2003.
